CRISPR knockdown tech from Doudna lab; plus CAR Ts for myasthenia gravis and more

Jennifer Doudna’s lab described in Nature Biotechnology an RNA-guided CRISPR technology to degrade target RNAs with high efficiency and minimal off-target effects.

The  University of California Berkeley team showed CRISPR–Csm, a multi-protein complex that is part of type III CRISPR immune systems in prokaryotes, lacks the off-target cleavage of cellular RNAs characteristic of Cas13, and single-vector delivery of the Streptococcus thermophilus Csm complex induced 90-99% target RNA knockdown in human cells. The University of California has filed a patent on the use of the Csm system for eukaryotic RNA knockdown...